Anlotinib inhibits synovial sarcoma by targeting GINS1: a novel downstream target oncogene in progression of synovial sarcoma

  • L. Tang
  • W. Yu
  • Y. Wang
  • H. Li
  • Z. ShenEmail author
Research Article



Synovial sarcoma (SS) is an aggressive soft-tissue sarcoma with a poor prognosis owing to its resistance to radiation and chemotherapy. Thus, novel therapeutic strategies for SS are urgently required. Anlotinib, a new oral tyrosine kinase inhibitor, is designed to primarily inhibit multi-targets in vasculogenesis and angiogenesis. This study was designed to characterize its antitumor efficacy and possible mechanism in patients with advanced refractory synovial sarcoma.


Anlotinib’s antitumor effect was evaluated in vivo and vitro. Downstream targets of anlotinib in treating synovial sarcoma were analyzed through microarray assay. Cell proliferation and apoptosis analyses were performed to evaluate the impact of candidate downstream gene depletion in synovial sarcoma cells. Microarray assay were carried out to investigate potential signal network related with candidate downstream gene.


Anlotinib significantly suppresses synovial sarcoma proliferation in PDTX model and cell lines. Additionally, GINS1 (also named as PSF1, Partner of SLD Five 1), rather than other conventional gene target, was demonstrated to be a vital target of anlotinib’s antitumor effect in synovial sarcoma through microarray assay. Expression of GINS1 was remarkably higher in synovial sarcoma tumor samples and related with poor outcome. Knockdown of GINS1 expression could remarkably inhibit proliferation and promote apoptosis in vitro. Meanwhile, through microarray assay, CITED2, EGR1, SGK1 and SPP1 were identified and further validated by qPCR/WB as downstream targets of GINS1.


Anlotinib might suppress proliferation of SS through a novel downstream GINS1-regulated network which plays a vital function in SS proliferation and also demonstrated that targeting the GINS1-regulated signal pathway could be a potential strategy for management of SS.


Anlotinib GINS1 Synovial sarcoma Proliferation Apoptosis 



This study was supported by NSFC (National Natural Science Foundation of China) to Zan Shen (no. 81672658), Wenxi Yu (no. 81502325) and National Key Research Project of Science & Technology Ministry (no. 2016YFC0106204) to Zan Shen.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. All applicable international, national, and/or institutional guidelines for the care and use of animals were followed. In this study, the Ethics Committees of Affiliated Sixth People’s Hospital, Shanghai Jiaotong University have approved all studies about human participants and animal experiments. All participants have written informed consents.

Informed consent

Informed consent was obtained from all individual participants included in the study.


  1. 1.
    Enzinger FM, Weiss SW. Soft tissue tumours. Chicago: Mosby, Inc; 2001.Google Scholar
  2. 2.
    Raney RB. Synovial sarcoma in young people: background, prognostic factors, and therapeutic questions. J Pediatr Hematol Oncol. 2005;27:207–11.CrossRefGoogle Scholar
  3. 3.
    Demetri GD. Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options. Semin Oncol. 2001;28:19–26.CrossRefGoogle Scholar
  4. 4.
    Sawyers CL. Imatinib GIST keeps finding new indications: successful treatment of dermatofibrosarcoma protuberans by targeted inhibition of the platelet-derived growth factor receptor. J Clin Oncol. 2002;20:3568–9.CrossRefGoogle Scholar
  5. 5.
    Strumberg D, Richly H, Hilger RA, Schleucher N, Korfee S, Tewes M, Faghih M, Brendel E, Voliotis D, Haase CG, Schwartz B, Awada A, Voigtmann R, Scheulen ME, Seeber S. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol. 2005;23(5):965–72.CrossRefGoogle Scholar
  6. 6.
    Mross K, Frost A, Steinbild S, Hedbom S, Büchert M, Fasol U, Unger C, Krätzschmar J, Heinig R, Boix O, Christensen O. A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors. Clin Cancer Res. 2012;18(9):2658–67.CrossRefGoogle Scholar
  7. 7.
    Huang L, Huang Z, Bai Z, Xie R, Sun L, Lin K. Development and strategies of VEGFR-2/KDR inhibitors. Future Med Chem. 2012;4(14):1839–52.CrossRefGoogle Scholar
  8. 8.
    Sun Y, Niu W, Du F, Du C, Li S, Wang J, Li L, Wang F, Hao Y, Li C, Chi Y. Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors. J Hematol Oncol. 2016;9(1):105.CrossRefGoogle Scholar
  9. 9.
    Salim H, Zong D, Haag P, Novak M, Mork B, Lewensohn R, Lundholm L, Viktorsson K. Dkk1 is a potential novel mediator of cisplatin-refractoriness in non-small cell lung cancer cell lines. BMC Cancer. 2015;15:628.CrossRefGoogle Scholar
  10. 10.
    Takayama Y, Kamimura Y, Okawa M, Muramatsu S, Sugino A, Araki HGINS. a novel multiprotein complex required for chromosomal DNA replication in budding yeast. Genes Dev. 2003;17(9):1153–65.CrossRefGoogle Scholar
  11. 11.
    Bauerschmidt C, Pollok S, Kremmer E, Nasheuer HP, Grosse F. Interactions of human Cdc45 with the Mcm2-7 complex, the GINS complex, and DNA polymerases delta and epsilon during S phase. Genes Cells. 2007;12:745–58.Google Scholar
  12. 12.
    Gambus A, Jones RC, Sanchez-Diaz A, Kanemaki K, van Deursen F, Edmondson RD, Labib K. GINS maintains association of Cdc45 with MCM in replisome progression complexes at eukaryotic DNA replication forks. Nat Cell Biol. 2006;8:358–66.CrossRefGoogle Scholar
  13. 13.
    Kanemaki M, Sanchez-Diaz A, Gambus A, Labib K. Functional proteomic identification of DNA replication proteins by induced proteolysis in vivo. Nature. 2003;423:720–4.CrossRefGoogle Scholar
  14. 14.
    Moyer SE, Lewis PW, Botchan MR. Isolation of the Cdc45/Mcm2-7/GINS (CMG) complex, a candidate for the eukaryotic DNA replication fork helicase. Proc Natl Acad Sci. 2006;103:10236–41.CrossRefGoogle Scholar
  15. 15.
    Pacek M, Tutter AV, Kubota Y, Takisawa H, Walter JC. Localization of MCM2-7, Cdc45, and GINS to the site of DNA unwinding during eukaryotic DNA replication. Mol Cell. 2006;21:581–7.CrossRefGoogle Scholar
  16. 16.
    Ueno M, Itoh M, Kong L, Sugihara K, Asano M, Takakura N. PSF1 is essential for early embryogenesis in mice. Mol Cell Biol. 2005;25(23):10528–32.CrossRefGoogle Scholar
  17. 17.
    Nakahara I, Miyamoto M, Shibata T, Akashi-Tanaka S, Kinoshita T, Mogushi K, Oda K, Ueno M, Takakura N, Mizushima H, Tanaka H, Ohta T. Up-regulation of PSF1 promotes the growth of breast cancer cells. Genes Cells. 2010;15(10):1015–24.CrossRefGoogle Scholar
  18. 18.
    Zhou L, Sun XJ, Liu C, Wu QF, Tai MH, Wei JC, Lei L, Meng FD, Qu K, Xu J. Overexpression of PSF1 is correlated with poor prognosis in hepatocellular carcinoma patients. Int J Biol Markers. 2015;30(1):e56–64.CrossRefGoogle Scholar
  19. 19.
    Zhang J, Wu Q, Wang Z, Zhang Y, Zhang G, Fu J, Liu C. Knockdown of PSF1 expression inhibits cell proliferation in lung cancer cells in vitro. Tumour Biol. 2015;36(3):2163–8.CrossRefGoogle Scholar
  20. 20.
    Tahara H, Naito H, Kise K, Wakabayashi T, Kamoi K, Okihara K, Yanagisawa A, Nakai Y, Nonomura N, Morii E, Miki T, Takakura N. Evaluation of PSF1 as a prognostic biomarker for prostate cancer. Prostate Cancer Prostatic Dis. 2015;18(1):56–62.CrossRefGoogle Scholar
  21. 21.
    Kanzaki R, Naito H, Kise K, Takara K, Eino D, Minami M, Shintani Y, Funaki S, Kawamura T, Kimura T, Okumura M, Takakura N. PSF1 (Partner of SLD Five 1) is a Prognostic biomarker in patients with non-small cell lung cancer treated with surgery following preoperative chemotherapy or chemoradiotherapy. Ann Surg Oncol. 2016;23(12):4093–100.CrossRefGoogle Scholar
  22. 22.
    Nagahama Y, Ueno M, Miyamoto S, Morii E, Minami T, Mochizuki N, Saya H. Takakura N.PSF1, a DNA replication factor expressed widely in stem and progenitor cells, drives tumorigenic and metastatic properties. Cancer Res. 2010;70(3):1215–24.CrossRefGoogle Scholar
  23. 23.
    Sun HB, Zhu YX, Yin T, Sledge G, Yang YC. MRG1, the product of a melanocyte-specific gene related gene, is a cytokine-inducible transcription factor with transformation activity. Proc Natl Acad Sci USA. 1998;95:13555–60.CrossRefGoogle Scholar
  24. 24.
    Bai L, Merchant JL. A role for CITED2, a CBP/p300 interacting protein, in colon cancer cell invasion. FEBS Lett. 2007;581:5904–10.CrossRefGoogle Scholar
  25. 25.
    Zhao N, Stoffel A, Wang PW, Eisenbart JD, Espinosa R, Larson RA, et al. Molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases to 1–1.5 Mb and preparation of a PAC-based physical map. Proc Natl Acad Sci USA. 1997;94(13):6948–53.CrossRefGoogle Scholar
  26. 26.
    Gururajan M, Simmons A, Dasu T, Spear BT, Calulot C, Robertson DA, et al. Early growth response genes regulate B cell development, proliferation, and immune response. J Immunol. 2008;181(7):4590–602.CrossRefGoogle Scholar
  27. 27.
    Mora A, Komander D, Van Aalten DMF, Alessi DR. PDK1, the master regulator of AGC kinase signal transduction. Semin Cell Dev Biol. 2004;15:161–70.CrossRefGoogle Scholar
  28. 28.
    Talarico C, Dattilo V, D’Antona L, Menniti M, Bianco C, Ortuso F, Alcaro S, Schenone S, Perrotti N, Amato R. SGK1, the new player in the game of resistance: chemo-radio molecular target and strategy for inhibition. Cell Physiol Biochem. 2016;39(5):1863–76.CrossRefGoogle Scholar
  29. 29.
    Anborgh PH, Mutrie JC, Tuck AB, Chambers AF. Role of the metastasis-promoting protein osteopontin in the tumour microenvironment. J Cell Mol Med. 2010;14:2037–44.CrossRefGoogle Scholar
  30. 30.
    Rittling SR, Chambers AF. Role of osteopontin in tumour progression. Br J Cancer. 2004;90:1877–81.CrossRefGoogle Scholar

Copyright information

© Federación de Sociedades Españolas de Oncología (FESEO) 2019

Authors and Affiliations

  1. 1.Department of Oncology, Affiliated Sixth People’s HospitalShanghai Jiaotong UniversityShanghaiPeople’s Republic of China

Personalised recommendations